Kidney Fibrosis – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Kidney Fibrosis – Pipeline Review, H1 2020’, provides an overview of the Kidney Fibrosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Kidney Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Kidney Fibrosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Kidney Fibrosis

– The report reviews pipeline therapeutics for Kidney Fibrosis by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Kidney Fibrosis therapeutics and enlists all their major and minor projects

– The report assesses Kidney Fibrosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Kidney Fibrosis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Kidney Fibrosis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Kidney Fibrosis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AdAlta Ltd

Algernon Pharmaceuticals Inc

Angion Biomedica Corp

BiOrion Technologies BV

Blade Therapeutics Inc

Cellmid Ltd

Curacle Co Ltd

Epigen Biosciences Inc

Evotec SE

Future Medicine Co Ltd

Galapagos NV

Galectin Therapeutics Inc

GenKyoTex SA

iBio Inc

Isarna Therapeutics GmbH

Kadmon Corp LLC

Liminal BioSciences Inc

Max Biopharma Inc

MedPacto Inc

Mission Therapeutics Ltd

NB Health Laboratory Co Ltd

Novo Nordisk AS

Oasis Pharmaceuticals LLC

Osteoneurogen Inc

Pharmaxis Ltd

Redx Pharma Plc

Sanofi

Scholar Rock Inc

Senolytic Therapeutics Inc

TiumBio Co Ltd

TRACON Pharmaceuticals Inc

Transcenta Holding Ltd

Vascular Biogenics Ltd

Vectus Biosystems Ltd

Table of Contents

Table of Contents

Introduction

Kidney Fibrosis - Overview

Kidney Fibrosis - Therapeutics Development

Kidney Fibrosis - Therapeutics Assessment

Kidney Fibrosis - Companies Involved in Therapeutics Development

Kidney Fibrosis - Drug Profiles

Kidney Fibrosis - Dormant Projects

Kidney Fibrosis - Discontinued Products

Kidney Fibrosis - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Kidney Fibrosis, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Kidney Fibrosis – Pipeline by AdAlta Ltd, H1 2020

Kidney Fibrosis – Pipeline by Algernon Pharmaceuticals Inc, H1 2020

Kidney Fibrosis – Pipeline by Angion Biomedica Corp, H1 2020

Kidney Fibrosis – Pipeline by BiOrion Technologies BV, H1 2020

Kidney Fibrosis – Pipeline by Blade Therapeutics Inc, H1 2020

Kidney Fibrosis – Pipeline by Cellmid Ltd, H1 2020

Kidney Fibrosis – Pipeline by Curacle Co Ltd, H1 2020

Kidney Fibrosis – Pipeline by Epigen Biosciences Inc, H1 2020

Kidney Fibrosis – Pipeline by Evotec SE, H1 2020

Kidney Fibrosis – Pipeline by Future Medicine Co Ltd, H1 2020

Kidney Fibrosis – Pipeline by Galapagos NV, H1 2020

Kidney Fibrosis – Pipeline by Galectin Therapeutics Inc, H1 2020

Kidney Fibrosis – Pipeline by GenKyoTex SA, H1 2020

Kidney Fibrosis – Pipeline by iBio Inc, H1 2020

Kidney Fibrosis – Pipeline by Isarna Therapeutics GmbH, H1 2020

Kidney Fibrosis – Pipeline by Kadmon Corp LLC, H1 2020

Kidney Fibrosis – Pipeline by Liminal BioSciences Inc, H1 2020

Kidney Fibrosis – Pipeline by Max Biopharma Inc, H1 2020

Kidney Fibrosis – Pipeline by MedPacto Inc, H1 2020

Kidney Fibrosis – Pipeline by Mission Therapeutics Ltd, H1 2020

Kidney Fibrosis – Pipeline by NB Health Laboratory Co Ltd, H1 2020

Kidney Fibrosis – Pipeline by Novo Nordisk AS, H1 2020

Kidney Fibrosis – Pipeline by Oasis Pharmaceuticals LLC, H1 2020

Kidney Fibrosis – Pipeline by Osteoneurogen Inc, H1 2020

Kidney Fibrosis – Pipeline by Pharmaxis Ltd, H1 2020

Kidney Fibrosis – Pipeline by Redx Pharma Plc, H1 2020

Kidney Fibrosis – Pipeline by Sanofi, H1 2020

Kidney Fibrosis – Pipeline by Scholar Rock Inc, H1 2020

Kidney Fibrosis – Pipeline by Senolytic Therapeutics Inc, H1 2020

Kidney Fibrosis – Pipeline by TiumBio Co Ltd, H1 2020

Kidney Fibrosis – Pipeline by TRACON Pharmaceuticals Inc, H1 2020

Kidney Fibrosis – Pipeline by Transcenta Holding Ltd, H1 2020

Kidney Fibrosis – Pipeline by Vascular Biogenics Ltd, H1 2020

Kidney Fibrosis – Pipeline by Vectus Biosystems Ltd, H1 2020

Kidney Fibrosis – Dormant Projects, H1 2020

Kidney Fibrosis – Dormant Projects, H1 2020 (Contd..1), H1 2020

Kidney Fibrosis – Discontinued Products, H1 2020

List of Figures

List of Figures

Number of Products under Development for Kidney Fibrosis, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports